Takahashi T, Conforti A, Kikumoto Y, Hoon D S, Morton D L, Irie R F
Department of Biotechnology Sciences, John Wayne Cancer Institute, Santa Monica, California.
J Clin Immunol. 1998 Jul;18(4):299-305. doi: 10.1023/a:1027342024618.
We previously reported that gp43 tumor-associated antigen peptide (DLTMKYQIF; designated 810 antigen) on human melanoma cells is recognized by IgM human monoclonal antibody L92 and by cytotoxic T lymphocytes (CTL). In this study, we retrospectively tested sera of 44 patients with regional metastatic melanoma (22 who recurred within 1 year and 22 who survived longer than 5 years) to determine if antibody responses to 810 antigen could be induced by immunization with an allogeneic melanoma cell vaccine that contained 810 peptide. IgM and IgG antibodies were assessed by enzyme-linked immunosorbent assay using a synthetic 810 nonamer peptide. A significant augmentation of IgM antibody was demonstrated 4 weeks after initiation of vaccine therapy, and the IgM level was significantly higher in patients who survived more than 5 years. The antigen epitope recognized by antibodies was located within TMKYQI. Of this epitope sequence, K appears to play a central role in antigenicity. The 810 antigen recognized by antibody and CTL may have clinical relevance as a potential source of melanoma vaccine.
我们之前报道过，人黑色素瘤细胞上的gp43肿瘤相关抗原肽（DLTMKYQIF；命名为810抗原）可被IgM人单克隆抗体L92以及细胞毒性T淋巴细胞（CTL）识别。在本研究中，我们回顾性检测了44例局部转移性黑色素瘤患者（22例在1年内复发，22例存活超过5年）的血清，以确定用含810肽的同种异体黑色素瘤细胞疫苗免疫是否能诱导对810抗原的抗体反应。使用合成的810九聚体肽通过酶联免疫吸附测定法评估IgM和IgG抗体。疫苗治疗开始4周后，IgM抗体显著增加，且存活超过5年的患者IgM水平显著更高。抗体识别的抗原表位位于TMKYQI内。在该表位序列中，K似乎在抗原性中起核心作用。抗体和CTL识别的810抗原作为黑色素瘤疫苗的潜在来源可能具有临床相关性。
